A review of the clinical and epidemiological aspects of Guillain-Barré syndrome in patients infected with SARS-CoV-2: An Extended Comprehensive Review
Resumen
Since 2019, cases of patients with COVID-19 who developed Guillain-Barré Syndrome (GBS) have been reported. This review explores mechanisms that explain pathophysiology, clinical features, laboratory findings, and imaging characteristics in these patients.Methodology: A bibliographic search was made of studies on the topic published in NCBI and Scielo, between December 2019 and April 2022.Results: Ninety articles were found, 53 of which were included in this article. No studies were found that explain an association between GBS and COVID19. Specific clinical manifestations found were areflexia (56.95%), hyporeflexia (19.44%), muscle weakness (65.28%), gait disturbance (12.5%), hypoesthesia (26.39%), paresthesia (30.55%), and micturition disturbance (6.94%). The CSF findings included albumin-cytological dissociation (66.67%), and an average protein level of 140.23 mg/dL (SD: 106.71). Some cases reported enhancement of the cervical leptomeningeal, brainstem and cranial nerves on magnetic resonance imaging tests. The predominant variant of GBS was acute inflammatory demyelinating polyneuropathy (56.94%). The findings in the nerve conduction studies were the absence of F waves (61.54%), increased distal motor latency (80%), decreased motor amplitude (93.1%), and decreased motor conduction velocity (75%). In addition, the nerves mainly involved were the tibial (20.21%), peroneal (24.47%), median (20.21%), and ulnar (18.09%). The most frequent alteration of cranial nerves was bilateral (25%) and unilateral (13.89%) facial palsy.Conclusion: The primary GBS variant was Acute Inflammatory Demyelinating Polyneuropathy. Cerebrospinal fluid analysis revealed albumin-cytological dissociation as the most common finding, and MRI tests showed cranial nerves enhancements. An additional differential feature was the lower commitment of the autonomous system.
Referencias
Coronavirus [Internet]. Mhmedical.com. [cited March 20, 2022]. Available in: https://accessmedicina.mhmedical.com/content.aspx?bookid=1507§ionid=102896371
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications. 2020 Mar 27; 11(1):1620.
COVID-19 map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited March 20, 2022]. Available in: https://coronavirus.jhu.edu/map.html
Peru [Internet]. Johns Hopkins Coronavirus Resource Center. [cited March 20, 2022]. Available in: https://coronavirus.jhu.edu/region/peru
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020; 382(18): 1708-1720. doi:10.1056/NEJMoa2002032
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374. doi:10.1056/NEJMc2010419
Escobar G, Matta J, Taype-Huamaní W, Ayala R, Amado J. Características clínico-epidemiológicas de pacientes fallecidos por COVID-19 en un hospital nacional de Lima, Perú. Rev Fac Med Hum. 2020;20(2):180-185. doi 10.25176/RFMH.v20i2.2940
Ebrahim Z, Rahmani F, Rezaei N. Autoimmunity and cytokines in Guillain-Barre syndrome revisited: review of pathomechanisms with an eye on therapeutic options. Eur Cytokine Netw. 2019; 30(1):1-14. doi: 10.1684/ecn.2019.0424
Filosto M, Cotti S, Gazzina S, Foresti C, Frigeni B, Servalli M et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021;92(7):751-756. doi:10.1136/jnnp-2020-324837
Willison H, Jacobs B, van Doorn P. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333(21):1374-1379. doi:10.1056/NEJM199511233332102
Hao Y, Wang W, Jacobs BC, Qiao B, Chen M, Liu D, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol. 2019 Dec; 6(12):2510-2517. doi: 10.1002/acn3.50946.
McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001;153(6):610-614. doi:10.1093/aje/153.6.610
Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One. 2007;2(4):e344. Published 2007 Apr 4. doi:10.1371/journal.pone.0000344
Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet. 2016; 387(10027):1531–9. doi: 10.1016/S0140-6736(16)00562-6
Barbi L, Coelho AVC, Alencar LCA de, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. The Brazilian Journal of Infectious Diseases. Braz J Infect Dis. 2018;22(2):137-141. doi:10.1016/j.bjid.2018.02.005.
Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Castañeda CC, Dioses JA, et al. Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e952. Published 2021 Feb 5. doi:10.1212/NXI.0000000000000952
Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, Vizcarra JA. COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res. 2020;5:107. doi:10.12688/wellcomeopenres.15987.2
Khan Z, Ahmad U, Ualiyeva D, Amissah OB, Khan A, Noor Z, et al. Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?, Clinical Immunology Communications. 2022;2:1-5,https://doi.org/10.1016/j.clicom.2021.12.002.
Jumagaliyeva MB, Ayaganov DN, Abdelazim IA, Saparbayev SS, Tuychibaeva NM, Kurmambayev YJ. Relation between Guillain-Barré syndrome and Covid-19: Case-Series. J Med Life. 2023;16(9):1433-1435. doi: 10.25122/jml-2023-0275.
Aasfara J, Hajjij A, Bensouda H, Ouhabi H, Benariba F. A unique association of bifacial weakness, paresthesia, and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report. Pan Afr Med J. 2021; 38:1–5. doi:10.11604/pamj.2021.38.30.27646
Chakraborty U, Hati A, Chandra A. Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication. Diabetes Metab Syndr. 2021;15(6):102326. doi:10.1016/j.dsx.2021.102326
Mohammadi SM, Abdi R, Karimi Z, Mortazavi F. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report. J Med Case Rep. 2022;16(1):63. doi:10.1186/s13256-021-03245-y
Lahiri D, Ardila A. COVID-19 pandemic: a neurological perspective. Cureus. 2020; 12:e7889. doi:10.7759/cureus.7889
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22. doi:10.1016/j.bbi.2020.03.031
Ahmed MU, Hanif M, Ali MJ, Haider MA, Kherani D, Memon GM, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front Neurol. 2020; 11:518. doi:10.3389/fneur.2020.00518
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020; 77:8-12. doi:10.1016/j.jocn.2020.05.017
Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Am J Emerg Med. 2020;38(7):1549.e3-1549.e7. doi:10.1016/j.ajem.2020.05.024
Tay M, Poh C, Rénia L, MacAry P, Ng L. The trinity of COVID-19: immunity, inflammation, and intervention. Nat. Rev. Immunol. 2020;20(6):363–374. doi: 10.1038/s41577-020-0311-8.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
Diez-Porras L, Vergés E, Gil F, Vidal MJ, Massons J, Arboix A. Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review. Neuromuscul Disord. 2020;30(10):859-861. doi:10.1016/j.nmd.2020.08.354
Wada S, Nagasaki Y, Arimizu Y, Shimo M, Matsukuma Y, Okamoto M, et al. Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection. Intern Med. 2020 Sep 1; 59(17):2187–9. doi:10.2169/internalmedicine.5447-20
McCray P, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007 Jan;81(2):813-21. doi: 10.1128/JVI.02012-06. Epub 2006 Nov 1. PMID: 17079315; PMCID: PMC1797474.
Arbour N, Day R, Newcombe J, Talbot P. Neuroinvasion by human respiratory coronaviruses. J. Virol. 2000;74(19):8913–8921. doi:10.1128/jvi.74.19.8913-8921.2000
Ivanov I, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496‐508. doi:10.1016/j.chom.2012.09.009
Katz-Agranov N, Zandman-Goddard G. Autoimmunity and COVID-19 - The microbiotal connection. Autoimmun Rev. 2021;20(8):102865. doi: 10.1016/j.autrev.2021.102865
Maccario M, Tarantino A, Nobile‐Orazio E, Ponticelli C. Campylobacter jejuni bacteremia and Guillain‐Barré syndrome in a renal transplant recipient. Transpl Int. 1998;11(6):439‐442. doi:10.1007/s001470050171
Zhang L, Arrington S, Keung Y. Guillain‐Barré syndrome after transplantation. Leuk Lymphoma. 2008;49(2):291‐297. doi:10.1080/10428190701760003
Meythaler JM. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil. 1997;78(8):872-879. doi:10.1016/s0003-9993(97)90203-3
Cosi V, Versino M. Guillain-Barré syndrome. Neurol Sci. 2006; 27 (Suppl 1): s47–s51. doi:10.1007/s10072-006-0548-4
Wang Y, Shang P, Xin M, Bai J, Zhou C, Zhang HL. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. BMC Neurol. 2017; 17: 200. doi:10.1186/s12883-017-0982-3
Yao S, Chen H, Zhang Q, Shi Z, Liu J, et al. Pain during the acute phase of Guillain-Barré syndrome. Medicine (Baltimore). 2018; 97(34):e11595. doi: doi:10.1097/MD.0000000000011595
Singh J, Raja V Sr, Irfan M, Hashmat O, Syed M, Shahbaz NN. Frequency of Autonomic Dysfunction in Patients of Guillain Barre Syndrome in a Tertiary Care Hospital. Cureus. 2020;12(12):e12101. doi: 10.7759/cureus.12101
Bhargava A, Banakar BF, Pujar GS, Khichar S. A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication. J Neurosci Rural Pract. 2014;5(Suppl 1):S43-S47. doi:10.4103/0976-3147.145200.
Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira M, Cornblath D, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019; 15: 671–683. https://doi.org/10.1038/s41582-019-0250-9.
Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. Radiology. 2020; 296(2):E72-E78. doi: doi:10.1148/radiol.2020201160
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020; 295(1):202-207. doi: 10.1148/radiol.2020200230
Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47(3):813-817. doi:10.1212/wnl.47.3.813
Byun WM, Park WK, Park BH, Ahn SH, Hwang MS, Chang JC. Guillain-Barré syndrome: MR imaging findings of the spine in eight patients. Radiology. 1998; 208(1):137-141. doi 10.1148/radiology.208.1.9646804
Alkan O, Yildirim T, Tokmak N, Tan M. Spinal MRI findings of Guillain-Barré syndrome. J Radiol Case Rep. 2009; 3(3):25-28. doi:10.3941/jrcr.v3i3.153
Fulbright RK, Erdum E, Sze G, Byrne T al. Cranial nerve enhancement in the Guillain-Barré syndrome. AJNR Am J Neuroradiol. 1995; 16(4 Suppl):923-925.
Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. SAGE Open Med Case Rep. 2019; 7:2050313X19838750. doi:10.1177/2050313X19838750
Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020; 382(26):2574-2576. doi:10.1056/NEJMc2009191
Li X, Wang Y, Wang H, Wang Y. SARS-CoV-2-associated Guillain-Barré syndrome is a para-infectious disease. QJM. 2021;114(9):625-635. doi:10.1093/qjmed/hcab157
Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018; 141(10):2866-2877. doi:10.1093/brain/awy232
Ye Y, Wang K, Deng F, Xing Y. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in northeastern China. Muscle Nerve. 2013; 47(1):68-71. doi:10.1002/mus.23477
Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126(Pt 10):2279-2290. doi:10.1093/brain/awg233
Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol. 2001; 58(6):913-917. doi:10.1001/archneur.58.6.913
Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539. doi:10.1016/S0140-6736(16)00562-6
Derechos de autor 2023 Alexander Cordero
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
La RNP se distribuye bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Los autores ceden sus derechos a la RNP para que esta divulgue el artículo a través de los medios que disponga. La revista proporcionará formatos de declaración jurada de autoría y autorización para la publicación del artículo, los cuales deben ser entregados junto al manuscrito.
Los autores mantienen el derecho a compartir, copiar, distribuir, ejecutar y comunicar públicamente su artículo, o parte de él, mencionando la publicación original en la revista. Los autores pueden archivar en el repositorio de su institución:
- La tesis de grado de la cual derive el artículo publicado.
- La versión pre-print: versión previa a la revisión por pares.
- La versión post-print: versión final posterior a la revisión por pares.
- La versión definitiva o versión final creada por el editor para su publicación.
